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Malignant pleural effusion (MPE), the presence of malignant cells
in pleural fluid, is often the first sign of many cancers and occurs in
patients with metastatic malignancies. Accurate detection of
tumor cells in pleural fluid is crucial because the presence of MPE
denotes an advanced stage of disease and directs a switch in clinical
managements. Cytology, as a traditional diagnostic tool, has limited
sensitivity especially when tumor cells are not abundant, and may
be confounded by reactive mesothelial cells in the pleural fluid. We
describe a highly sensitive approach for rapid detection of metabol-
ically active tumor cells in MPE via exploiting the altered glucose
metabolism of tumor cells relative to benign cells. Metabolically
active tumor cells with high glucose uptake, as evaluated by a
fluorescent glucose analog (2-NBDG), are identified by high-
throughput fluorescence screening within a chip containing
200,000 addressable microwells and collected for malignancy con-
firmation via single-cell sequencing. We demonstrate the utility of
this approach through analyzing MPE from a cohort of lung cancer
patients. Most candidate tumor cells identified are confirmed to
harbor the same driver oncogenes as their primary lesions. In some
patients, emergence of secondary mutations that mediate acquired
resistance to ongoing targeted therapies is also detected before re-
sistance is manifested in the clinical imaging. The detection scheme
can be extended to analyze peripheral blood samples. Our approach
may serve as a valuable complement to cytology in MPE diagnosis,
helping identify the driver oncogenes and resistance-leading muta-
tions for targeted therapies.
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Pleural effusion (PE) is associated with many types of malig-nancies, as exemplified by nonsmall cell lung cancer (NSCLC),
breast cancer, Koposi sarcoma, and lymphomas (1). The accurate
diagnosis of the etiology of the effusion, especially the identifi-
cation of malignant tumor cells in the pleural fluid, is of great
clinical significance for lung cancer patients, because the presence
of malignant cells in PE denotes an advanced stage of disease with
metastasis (M1a staging) and directs the patient management
from curative intent to palliative care (2).
Cytological analysis by thoracentesis is a traditional and min-
imally invasive diagnostic tool of MPE (2). However, it suffers a
low sensitivity of only ∼60% because of the difficulties in the
distinction among mesothelial, neoplastic, and reactive cells even
for highly experienced pathologists (1). Although inclusion of
immunohistochemistry (IHC) increases diagnostic sensitivity of
MPE (3), no universal marker of malignancy exists and IHC
staining based on a broad range of markers is time-consuming.
Many malignant effusions are hemorrhagic with red blood cells
and lymphocytes as predominant cell types (1). The number of
tumor cells in the effusion is relatively small and even rare for
patients who are in an early stage of metastasis or who have been
treated with chemotherapies or targeted therapies, further chal-
lenging the accurate diagnosis of MPE with cytology.
Recent advancement in detection of rare circulating tumor
cells (CTCs) in peripheral blood may present an opportunity to
identify malignant cells in other body fluids, such as PE (4).
However, most approaches available for detecting CTCs include
an enrichment step and a subsequent immunostaining-based
CTC identification. The enrichment step is generally based on
epithelial marker isolation, white blood cell depletion, or dis-
crimination of physical properties. The immunostaining-based
CTC identification, first adopted by the CellSearch system, in-
cludes cell fixation, permeabilization, and staining with a mixture
of anti-CD45 (common leukocyte marker), anti-cytokeratin (CK,
epithelial marker), and DAPI (cell nucleus marker) to pinpoint
epithelial cells in blood (5). Therefore, these approaches may not
be directly adapted to obtain a definitive diagnosis of a malig-
nant effusion, because they are incapable of distinguishing ma-
lignant tumor cells from benign epithelial cells and reactive
mesothelial cells in PE that also express epithelial markers (5).
The use of epithelial markers also intrinsically limits the di-
agnoses of pleural fluid of nonepithelial malignancies. Given the
important clinical implications of MPE, a new approach that
allows definitive diagnosis of malignant effusion through rapid
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and accurate identification of malignant tumor cells in PE is
greatly desired.
Here, we demonstrate an enrichment-free, metabolic-based
approach for high-throughput screening of metabolically active
tumor cell in PE samples via exploiting the innate difference in
glucose uptake between malignant tumor cells and benign cells
in lung cancer patients. Altered glucose metabolism is a hallmark
of many cancers (6). The enhanced glucose uptake as a result of
the glycolytic switch and elevated expression of glucose trans-
porters (GLUTs) in most cancer cells has been used in positron-
emission tomography (PET) to image malignant tumors in vivo.
In NSCLC patients, enhanced glycolysis and glucose oxidation
were observed in vivo for tumors relative to benign cells (7).
18F-fluoro-2-deoxy-D-glucose (FDG) uptake has been found to
correlate with tumor vitality with prognostic value in patient
response (8). Therefore, we hypothesize that the quantitation of
glucose uptake with fluorescent glucose analog 2-NBDG (9–12)
combined with leukocyte marker CD45 staining presents an
opportunity to functionally distinguish metabolically active ma-
lignant tumor cells from other nontumor cells in PE. With the
aid of a microchip device with addressable microwells and a
computerized high-speed fluorescent imaging system, this rapid
functional assay enables high-throughput screening of a large
number of cells at single cell resolution, leading to detection of
putative metabolically active tumor cells in pleural fluid without
enrichment. All cells assayed are addressable, and the candidate
tumor cells with high glucose uptake will therefore be retrieved
individually for single-cell sequencing to confirm their malig-
nancy and reveal their targetable driver oncogenes.
Results
Working Principle and Validation of the Detection Platform. The
detection of tumor cells in PE was performed in microwell chip
platform that accommodates 400 numbered blocks (Fig. 1A and
SI Appendix, Fig. S1) with 200,000 addressable microwells. The
experimental procedure is simple (Fig. 1B). Briefly, RBCs were
removed by an ammonium chloride-based lysis buffer, and all
nucleated cells were resuspended in HBSS and labeled with a
fluorescent anti-CD45 antibody. These cells were then applied
onto the microwell chip, sitting in an array of addressable
microwells (SI Appendix, Fig. S1), and incubated with a fluo-
rescent glucose analog 2-NBDG and EthD-1 (fluorescent dead
cell marker). After triple labeling with CD45/2-NBDG/EthD-1,
the microwell chip was imaged by a computerized high-speed
fluorescent microscope in three fluorescent colors (CD45, Cy5;
2-NBDG, FITC; EthD-1, TRITC) to capture ∼700 images (SI
Appendix, Fig. S2) in less than 10 min. A computational algo-
rithm analyzed the images and identified candidate tumor cells
that are viable (EthD-1−), CD45 negative, and exhibit high glu-
cose uptake (2-NBDGhigh), followed by reviewing via experi-
enced technicians. Once confirmed, the putative single tumor
cells were retrieved by an automatic micromanipulator sequen-
tially based on recorded addresses at a rate of 1 min per cell for
single-cell sequencing that serves as a main control for confir-
mation of the malignancy of identified cells.
2-NBDG is a fluorescent analog of D-glucose that follows a
similar metabolic pathway inside the cell. Prior work has shown
that 2-NBDG enters a cell via glucose transporters and is
phosphorylated at the C-6 position by hexokinases I–II. The
phosphorylated fluorescent metabolite, 2-NBDG-6-phosphate,
remains in the cell until decomposition into a nonfluorescent
form (9–13). Compared with nonmalignant cells, 2-NBDG is
rapidly taken up by malignant cells, providing an optical marker
for detection of malignant cells. As a proof-of-concept demon-
stration, we treated A549 (an NSCLC cell line) cells with
2-NBDG (Fig. 1C) and compared their signal against CD45-
labeled nucleated cells taken from three healthy donors’ blood
samples. Briefly, cells in the microwells were deprived of glucose
for 10 min and then exposed to 0.4 mM 2-NBDG and 4 μM
EthD-1 for 20 min at 37 °C. After extensive washing with cold
PBS, the fluorescence signals of 2-NBDG, CD45, and EthD-1
were measured for all the cells at single cell resolution. The
histograms of 2-NBDG uptakes are shown in Fig. 1D, in which a
clear separation between leukocytes and tumor cells supports the
feasibility of functionally discriminating metabolically active tu-
mor cells from leukocytes with 2-NBDG uptake (Fig. 1E). Sim-
ilar clear separation is also observed in the single-cell PET assay,
in which FDG, the radioactive glucose analog, was used to
quantitate glucose uptake of tumor cells and leukocytes (SI
Appendix, Fig. S3). Therefore, 2-NBDG is consistent with FDG
in quantifying in vitro glucose uptake of cells.
Identification of Metabolically Active Tumor Cells in PE Samples of
Lung Cancer Patients. After validation of our detection scheme
with lung cancer cell line, we tested the utility of our platform in
the PE samples from a cohort of NSCLC patients (SI Appendix,
Table S1). Briefly, approximately 500,000 nucleated cells labeled
with allophycocyanin (APC)-conjugated anti-CD45 antibody
were collected from each patient PE sample and applied onto a
microwell chip. Following the protocol previously described, we
identified putative metabolically active tumor cells with elevated
glucose uptake interspersed in a high background of other nu-
cleated cells presented in the PE, and retrieved them for single-
cell sequencing. To ensure the majority of candidate cells are
real tumor cells, we adapted the average 2-NBDG uptake of
A549 cells (fluorescence intensity ∼100) as the cutoff value for
Fig. 1. The microwell chip and the working principle. (A) A microwell chip
has 200,000 microwells with a diameter and the height of 25 μm and 20 μm,
respectively. (B) The working flow of the enrichment-free tumor cell de-
tection based on 2-NBDG uptake and CD45 expression. EthD-1−/CD45−/
2-NBDGhigh cells are identified as candidate tumor cells. (C) Bright field and
fluorescent images of A549 cells and leukocytes sitting in microwells of the
chip after treating with 2-NBDG. (D, Left) Histograms of 2-NBDG uptake in
nucleated cells taken from three healthy donors’ blood samples. (D, Right)
Histograms of 2-NBDG uptake of A549 cells suspended in HBSS or healthy
donor’s plasma. (E) Comparison of 2-NBDG uptake between nucleated cells
in healthy donor’s blood samples and tumor cell line A549. Statistical sig-
nificance was evaluated by Student’s t test (two-tailed ***P < 0.0001).
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metabolically active cells. As shown below, among all of the
patient PE samples tested, no leukocyte has 2-NBDG uptake
higher this cutoff value.
Fig. 2A shows representative images of candidate tumor cells
that are viable, CD45 negative, and exhibit high uptake of
2-NBDG (SI Appendix, Fig. S4) from the PE samples of patient
1. The histograms of 2-NBDG uptake in two typical blocks are
shown in Fig. 2B and presented in three distinct subpopulations.
Viable leukocytes (EthD-1−/CD45+) in the PE sample were
found to mostly exhibit low uptake of 2-NBDG with a small
number of cells exhibiting elevated uptake that was fewer than
100. Dead cells (EthD-1+) also showed a low unspecific back-
ground of 2-NBDG because of the diffusion of the 2-NBDG
molecules through the compromised cell membranes. In the
CD45− cells, observations of low 2-NBDG signal were poten-
tially from nonmalignant epithelial cells and mesothelial cells (SI
Appendix, Fig. S5) present in the PE (1). In 1 mL of this PE
sample, a total of five metabolically active candidate tumor cells
were identified based on the criteria of EthD-1−/CD45−/
2-NBDG>100 and then retrieved sequentially for single-cell se-
quencing of a small panel of oncogenes (EGFR, KRAS, PIK3CA,
BRAF, TP53) listed in SI Appendix, Table S2 (SI Appendix, Fig.
S6). We identified a G12C missense mutation at codon 12 in
exon 2 of KRAS, from a glycine to a cysteine (GGT > TGT) in
three of five candidate tumor cells (Fig. 2C and SI Appendix,
Table S3). The detected mutation was consistent with the mu-
tation status found in the primary lesion of the patient (SI Ap-
pendix, Table S1). The three cells harboring KRAS mutation are
therefore indeed tumor cells, confirming the malignant involvement
of PE for patient 1, who was diagnosed as MPE by traditional cy-
tology (Table 1).
To further resolve the mutational profile of the three cells with
KRAS mutation and determine the malignancy of the other two
cells, we performed the whole exome sequencing (WES) on
these five putative cells. We screened the mutations with the
Qiagen’s Lung Cancer Panel, containing 45 most relevant driver
oncogenes and tumor suppressor genes in lung cancer. A total of
26, 30, 23, 26, and 26 of 45 mutant genes are detected in cell 1
(mutant KRAS), cell 2 (mutant KRAS), cell 3 (wild-type KRAS),
cell 4 (wild-type KRAS), and cell 5 (mutant KRAS), respectively.
For all five cells, the number of nonsynonymous somatic mutations
and small insertions and deletions (INDELs) of the 45 genes is shown
in SI Appendix, Table S4 and Dataset S1, demonstrating a high
mutational frequency in these critical driver oncogenes. Cells 3 and 4,
while with wild-type KRAS, harbored missense mutations in the genes
including BRAF, EGFR, PIK3CA, PTEN, and TP53, and showed
similarity with the other three KRAS mutant tumor cells in the hi-
erarchical clustering (Fig. 2D), indicating a high chance of malignancy
of these two cells. As a result, all five metabolically active EthD-1−/
CD45−/2-NBDG>100 cells present in this PE sample were found
to be either harboring the same mutant KRAS as the primary
tumor or having high mutational frequency in other driver on-
cogenes, reassuring the validity of using glucose uptake as a
metabolic marker for pinpointing the candidate tumor cells.
In ∼500,000 nucleated cells from the PE sample from patient
3, 8 cells were identified as candidate tumor cells (Fig. 2E).
Single-cell sequencing at the target genes (SI Appendix, Table
S3) further showed that six of eight cells have an in-frame de-
letion in exon 19 of EGFR (E746_A750Del) and five of these six
Fig. 2. Identification of tumor cells in pleural effusion samples. (A) Candidate tumor cells (circled) from patient 1 that are EthD-1−/CD45−/2-NBDGhigh. (Scale
bars: 25 μm.) (B) The histograms of 2-NBDG uptake from two typical blocks with three subpopulations, including EthD-1+ cells (dead cells), EthD-1−/CD45+ cells
(viable leukocytes), and EthD-1−/CD45− cells. In these two blocks, four EthD-1−/CD45−/2-NBDG>100 cells were identified as candidate tumor cells. (C) Single-cell
Sanger sequencing results detected G12C missense mutation in exon 2 of KRAS from candidate tumor cells shown in A. (D) A clustering heat map of mu-
tational frequency in 45 driver oncogenes and tumor suppressors from WES results of five candidate tumor cells. Note that the number of mutations of a
gene was normalized to the largest number of missense mutation of that gene across the five cells. (Refer to SI Appendix, Table S4 for the list of genes).
(E ) Candidate tumor cells (circled) identified in PE sample from patient 3 with an in-frame deletion in exon 19 of EGFR. (F) Summary of 2-NBDG uptake
and mutational profile of the putative tumor cells from patient PE samples. Each row represents the 2-NBDG uptake and target gene sequencing for each
candidate tumor cell from the patient labeled at left. A red tile denotes a mutation in that gene, whereas a black tile denotes wild type (SI Appendix,
Table S3).
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cells also have a TP53R273H mutation (CGT > CAT). The de-
tected EGFR mutational status is consistent with the primary
site of the tumor, confirming the malignancy of the effusion for
this patient who has been concluded as MPE by cytology (Table
1). In the PE samples from patients 4, 6, 8, and 11, the same
MPE screening assay was successfully performed with our ap-
proach (Fig. 2F, Table 1, and SI Appendix, Table S3). In patient
4, we found two types of tumor cells harboring KRASG12D and
KRASG12V mutations, respectively, which is consistent with the
mutational status found in the primary lesion of this patient. For
patient 6, a total of 20 candidate tumor cells were picked out and
17 were found harboring the same EGFR19del (E746_A750Del)
as the primary lesion (Fig. 2F and SI Appendix, Table S3).
EGFRT790M mutation were also found in 12 of 17 tumor
cells where some of them were simultaneously harboring
PIK3CAE545K mutation as well (SI Appendix, Fig. S7). Both
EGFRT790M and PIK3CAE545Kmutations are reported to mediate
acquired resistance to EGFR tyrosine kinase inhibitors (TKI)
(14). Based on the clinical record, this patient received EGFR
TKI therapy and later on developed resistance to it. She had not
shown drug resistance in CT scans at the time of PE drawn.
However, the emergence of resistance-leading mutations was
clearly resolved via analyzing the metabolically active tumor cells
in the PE sample. We also compared the glucose uptake against
their cell sizes for the 17 malignant cells (SI Appendix, Fig. S8).
No statistically significant correlation was identified between the
cell size and the glucose uptake for these tumor cells. In the PE
sample from patient 8, who received chemotherapy and targeted
therapy (gefitinib), seven candidate tumor cells were identified
and sequenced to harbor EGFR19del (E746_T751Del) muta-
tion (Fig. 2F and SI Appendix, Table S3), whereas the primary
tumor had both EGFR19del and EGFRG719X mutations (SI
Appendix, Table S1). EGFRG719X mutation has been found to be
associated with increased sensitivity to the EGFR TKIs including
erlotinib and gefitinib (15, 16). The EGFRG719X mutant cells
were therefore likely to be preferentially eliminated in the pri-
mary lesion by gefitinib and were not found in the PE sample of
this patient. As negative controls, no metabolically active cells
were identified in PE samples from noncancer patients 12–15
who have benign effusion (Table 1 and SI Appendix, Fig. S9).
Heterogeneous CK Expression in High Glucose Uptake Lung Cancer
Cells. In the PE sample from patient 2 with an EGFRL858R mu-
tation in his primary lesion, six cells were identified as candidate
tumor cells (Fig. 3A and SI Appendix, Fig. S10). The sequencing
results (SI Appendix, Table S3) showed that four cells have the
consistent EGFRL858R mutation (CTG > CGG), and one cell has
both EGFRL858R mutation and PIK3CAE542K mutation (GAA >
AAA). EGFRT790M mutation is detected in two of six cells by an
amplification refractory mutation system (ARMS) assay. The
EGFRT790M and PIK3CAE542K mutations have been found to be
associated with drug resistance of EGFR TKI (14). The se-
quencing results are consistent with the fact that the patient
previously received the EGFR TKI therapy and started de-
veloping drug resistance at the time of PE drawn.
In addition to single-cell sequencing, this platform is also
compatible to immunofluorescent staining to characterize the
phenotype of the cells with high glucose uptake. In another PE
sample of patient 2, following on-chip metabolic assay, cells in
the microwells were fixed, permeablized, and immunostained
with phycoerythrin-conjugated CK (PE-CK). After imaging and
data analysis, candidate tumor cells were retrieved for single-cell
sequencing at the exon 21 of EGFR, which has a known mutation
of L858R. CD45−/EthD-1−/2-NBDG>100 tumor cells with de-
tected EGFRL858R mutation show heterogeneous CK expression
(Fig. 3B and SI Appendix, Figs. S11 and S12), and only ∼40% of
these tumor cells are found to be CK positive, indicating an in-
completeness in detection of tumor cells based solely on CK+/
CD45−/DAPI+ definition despite that it has been widely used in
detecting rare epithelial tumor cells circulating in peripheral
blood (17). A previous study on breast cancer patients where
50% of the HER2-amplified CTCs were found to be CK−/
CD45−/DAPI+ phenotype (18) echoes our observation. The
absence of CK expression on tumor cells of epithelial origin may
be attributed to epithelial-to-mesenchymal transition. Meanwhile,
CK+/2-NBDGlow cells harboring the tumor-specific EGFRL858R mu-
tation were also found in the sample (SI Appendix, Fig. S11), which
may be attributed to cell apoptosis.
Superior Performance in MPE Diagnosis Compared with Traditional
Cytology. Our platform outperforms cytological and IHC ap-
proaches in two representative scenarios. The first one involves
the inconclusive diagnosis of PE samples with traditional meth-
ods. For patient 10, initial cytological analysis found some sus-
picious cells in the PE but could not lead to a definitive diagnosis
because it failed to determine the malignancy of those cells. In
contrast, our platform identified five candidate metabolically
active tumor cells from ∼500,000 nucleated cells in the PE
Table 1. Comparison of our method to cytopathology and IHC results in MPE diagnosis
No. Cytology of PE IHC of PE
Our method on the same
PE samples
1 MPE TTF-1(+); P40(-); Napsin A(+); CK(+); CK7(+); Calretinin(−);
CD45/LCA(−); GLUT-1(+); CEA(+)
MPE, KRASG12C
2 MPE TTF-1(+); Calretinin(−); P40(−); CK(+); CD56(−) MPE, EGFRL858R, EGFRT790M, PIK3CAE542K
3 MPE TTF-1(+); Napsin A(+); CK(+); VIM(-); Calretinin(−); D2-40(−);
CK20(+); CK5/6(−); CK7(+); CD-X2(-)
MPE, EGFR19del
4 MPE TTF-1(-); Napsin A(-); CK(+); WT-1(−); Calretinin(−); D2-40(−);
CEA(+); CD15(+/−); CK5/6(−); CK7(+)
MPE, KRASG12D, KRASG12V
6 MPE TTF-1(+); Napsin A(+); CK(+); WT-1(−); Calretinin(−); D2-40(−);
CEA(+); CK5/6(−); CK7(+)
MPE, EGFR19del, EGFRT790M, PIK3CAE545K
7 UNSP NA MPE, EGFRL858R, BRAFV600E
8 MPE TTF-1(+); WT-1(−); Calretinin(+/−); D2-40(+/−); GLUT-1(+); Napsin A(+/−) MPE, EGFR19del
9 UNSP NA MPE, EGFRL858R, EGFRT790M
10 UNSP TTF-1(+); CK(+); WT-1(−); Calretinin(+); D2-40(−); CEA(+); GLUT-1(+);
HBME-1(+) *
MPE, ALK fusion gene
11 MPE TTF-1(+); Napsin A(-); WT-1(−); CK(+); Calretinin(−); D2-40(−); CK5/6(−);
CK7(+); CEA(+);GLUT-1(+)
MPE, EGFR19del
12–15 Benign PE NA Benign PE
Mutations on actionable oncogenes in bold are those resistant-leading secondary mutations different from primary tumors. CEA, carcinoembryonic
antigen; D2-40, podoplanin; LCA, leucoyte common antigen, namely CD45; UNSP, unspecified; WT-1, Wilms tumor protein.
*IHC result of patient 10 was from biopsy of mediastinal lymph node rather than thoracentesis.
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sample of this patient. Single-cell sequencing showed that these
cells are free of mutations in EGFR, KRAS, BRAF, and PIK3CA
(SI Appendix, Table S3). However, transcriptome amplification
of identified cells revealed the echinoderm microtubule-associ-
ated protein-like 4–anaplastic lymphoma kinase (EML4-ALK)
fusion oncogene, which is consistent with the mutational status of the
primary lesion, and the exclusive nature of the EML4-ALK rear-
rangement in NSCLC (19). In addition, immunostaining on the can-
didate tumor cells with thyroid transcription factor-1 (TTF-1) revealed
a phenotype of CD45−/TTF-1+/2-NBDG>100, indicating an origin of
lung adenocarcinoma. These results lead to a conclusive malignant
pleural involvement and are consistent with the IHC staining on
the patient biopsy of mediastinal lymph node (Table 1).
The second scenario is related to MPE diagnosis for patients
who are being treated with and respond to chemotherapy or
targeted therapies. For these patients, tumor cells in the effusion
serve as valuable resources for revealing any secondary muta-
tions associated with the onset of therapy resistance in the clinic.
However, the number of tumor cells present in the effusion is
usually small and even rare after drug treatment, posing a sig-
nificant technical challenge for cytology. For example, patient 7
with a primary tumor harboring EGFRL858R mutation received
chemo- and EGFR TKI gefitinib initially (SI Appendix, Table
S1). However, the tumor cells became resistant to gefitinib in less
than 7 mo. The patient then received alectinib and AZD9191, an
irreversible third-generation EGFR TKI. At the time of PE
draw, cytological and IHC analyses failed to detect tumor cells in
the effusion (Table 1). However, three candidate tumor cells
were identified by our platform in the effusion from this patient
and sequenced to harbor both EGFRL858R and BRAFV600E mu-
tations (Fig. 2F and Table 1). The acquired BRAFV600E mutation
was reported to be associated with decreased sensitivity to gefi-
tinib (20), which may account for the rapid resistance develop-
ment to gefitinib after an initial response.
Similarly, patient 9 with an EGFR19del in the primary tumor
was treated with alectinib, an EGFR TKI (SI Appendix, Table
S1). Cytological analysis failed to detect tumor cells in the PE
sample drawn after the targeted therapy (Table 1). Our platform
identified nine candidate tumor cells in the PE sample in which
six of them harbor EGFRL858R mutation and one cell harbors
both EGFRL858R and EGFRT790M mutations (Fig. 2F and SI
Appendix, Fig. S13 and Table S3). The inconsistent mutational
profiles between the primary tumor before targeted therapy and
the tumor cells found in PE after therapy may be attributed to
the tumor heterogeneity and clonal selection following the
therapy. The emergence of secondary EGFRT790M mutations
may imply an onset of resistance to alectinib in this patient.
Extension to the CTC Detection in Peripheral Blood Sample of Lung
Cancer Patients. The enrichment-free, simple metabolic-based
assay for identifying malignant cells in PE can be extended to
detect rare tumor cells in other body fluids, such as CTCs in
peripheral blood samples. In 1 mL of peripheral blood sample
from patient 4, after lysis of RBCs, all nucleated cells were ap-
plied onto the microwell chip at a concentration of ∼600,000
cells per chip. Two candidate CTCs were identified based on the
EthD-1−/CD45−/2-NBDG>100 criteria, and confirmed to be
malignant cells bearing KRASG12D mutation (Fig. 4), which is
consistent with the mutational status found in PE and primary
lesions (Table 1 and SI Appendix, Tables S1 and S3). Likewise, in
1 mL of peripheral blood sample from patient 3, eight candidate
CTCs were identified and four of them were found harboring
EGFR19del mutation, which is identical to the mutational status
found in PE and primary lesions (Fig. 4C). We further chal-
lenged our detection scheme for identifying CTCs for patients at
early clinical stage. In 1 mL of peripheral blood sample from
patient 5 (stage Ib), three candidate CTCs were successfully
identified and two of them were found harboring a EGFRA864V
mutation (GCG > GTG) in exon 21, as shown in Fig. 4 B and C.
Discussion
The accurate evaluation of PE is critical in the clinic because it
directs the staging and clinical managements of lung cancer pa-
tients. Pleural thoracentesis followed by the cytological analysis
is the least invasive approach for diagnosing MPE in the clinic.
Unfortunately, this approach has a large variation in sensitivity
depending on the fluid amount and quality, and the experience
of the cytopathologists (21). The existence of mesothelial cells
with atypical nuclear changes that resemble the malignant cells
further elevates the diagnostic threshold and confounds the
sensitivity of cytology. As a representative scenario in the clinic,
lung cancer patients with early stage metastasis often have a
positive chest computed tomography (CT) scan for lung lesions,
but a negative or inconclusive diagnosis for MPE because the
cytopathological analysis is insensitive to MPE samples with rare
Fig. 3. CK expression in high glucose uptake tumor cells. (A) Representative images of candidate tumor cells (circled) identified in the PE sample from patient
2 with single-cell sequencing results showing the EGFRL858 and PIK3CAE542K mutations. (B) Candidate tumor cells with EGFRL858 mutation were stained with
PE-CK and showed heterogeneous expression of CK.
Fig. 4. Representative fluorescence images of CTCs (circled) identified in
peripheral blood samples from patient 4 (A) and patient 5 (B). (C) Histo-
grams of 2-NBDG uptake for blood samples of patients 3, 4, and 5.
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tumor cells interspersed in a large number of blood cells (22).
In this case, pleural biopsy or thoracoscopic surgery will nor-
mally be indicated for more accurate evaluation of malignant
pleural involvement and metastasis. However, these invasive
approaches require general anesthesia and may induce signif-
icant patient morbidity and increased health care costs and,
thus, sometimes are not a good option for patients with ad-
vanced-stage disease (23).
Motivated by these clinical challenges, we have developed a
metabolic-based high-throughput screening approach to rapidly
identify rare tumor cells at single cell resolution in a high
background of leukocytes, followed by single-cell sequencing for
confirmation of malignancy and identification of targetable
driver oncogenes. In contrast to the cytological diagnosis of MPE
that normally requires more than 50 mL of effusion (24), this
strategy is capable to detect rare malignant tumor cells in less
than 1 mL of effusion fluid. Therefore, it can potentially be ex-
tended to detect CTCs in peripheral blood because that has al-
ready been demonstrated in patients 3, 4, and 5, given the utility
of this approach for blood analysis requires more comprehensive
evaluation in statistical number of patients.
High glucose-uptake tumor cells represent a metabolically
active subset of viable tumor cells present in PE or peripheral
blood (25). These tumor cells are prone to being more glycolytic
and, therefore, might have the potential to seed metastasis or
home to primary tumor sites. It has been shown that glucose
uptake of malignant cells in PE is an independent prognostic
indicator in NSCLC (26). More work is ongoing to validate the
clinical relevance and therapeutic importance of this metaboli-
cally active subset. In this study, we set a high threshold
(2-NBDG > 100) for discriminating leukocytes and tumor cells,
aiming to ensure most candidate cells for sequencing are tumor
cells. The successful detection of malignant tumor cells in all
MPE samples where no leukocyte has 2-NBDG uptake of more
than 100 further supports the validity of this cutoff value in our
system. It is worthwhile to note that the optimal cutoff value of
2-NBDG is system-specific, depending on the tumor type under
study, the processing and staining protocols, and the instru-
mental settings, and needs to be redetermined when working on
a new system. Importantly, the storage and shipping of PE and
peripheral blood samples may compromise the viability of tumor
cells and, therefore, induce a decrease in glucose uptake. All
samples should be processed and characterized immediately af-
ter collection from patients.
Given its capability of identifying rare tumor cells in minimal
amount of PE and its feasibility of implementing a standardized
and automatable assay protocol, our detection platform has the
potential to be used in conjunction with traditional cytology in
the clinic to provide a more sensitive assessment when cytology
alone fails to provide a definitive diagnosis of MPE (Table 1).
It is beneficial to patients with early stage metastasis and in-
conclusive MPE diagnoses where a reassessment by our ap-
proach could potentially release them from more invasive
interventions (as patient 10). In addition, both our data and the
data published elsewhere (27) have shown a high concordance
rate of mutational profile between tumor cells in MPEs and
primary tumor specimens for NSCLC patients. Therefore, our
approach offers a minimally invasive means for resolving targetable
mutations at single cell resolution, when the mutational profile of
the primary tumor site is not available for a patient (as patient 5),
which is frequently encountered in the clinic (28, 29). Furthermore,
patients are more likely to accept repeated thoracentesis rather
than rebiopsy of the primary tumor to detect molecular changes
(27), which makes our detection approach promising in monitoring
the change in mutational profile and the emergence of any sec-
ondary mutations at the onset of resistance during targeted ther-
apies. Of course, these utilities require extensive prospective or
retrospective validations on clinical samples first, and our work sets
a stage for such clinical studies in the future.
Materials and Methods
PE and blood samples were obtained from lung cancer patients in Shanghai
Chest hospital and Shanghai Municipal Hospital of Traditional Medicine with
informed consent. The experimental protocols have been approved by Ethics
and Scientific Committees of both hospitals. Please refer to SI Appendix, SI
Materials and Methods for cell lines and reagents used, microwell chip
fabrication, and protocols for tumor cell identification and sequencing.
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